BioAge Labs completes $238.3M IPO to develop muscle-preserving weight loss drug azelaprag.

BioAge Labs, a biopharmaceutical company, has completed its IPO, raising $238.3 million to develop its weight loss drug, azelaprag, which aims to preserve muscle mass during weight loss. This sets it apart from major competitors like Novo Nordisk and Eli Lilly. As a clinical-stage company, BioAge Labs faces significant risks and uncertainty, potentially making it a high-reward investment, but investors may prefer the stability of established players for now.

October 12, 2024
4 Articles

Further Reading